Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed...

CheckMate 743: First-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectabl...Подробнее

CheckMate 8HW: first-line nivolumab plus ipilimumab in MSI-H/dMMR mCRCПодробнее

Comment: Nivolumab plus ipilimumab combination for advanced NSCLCПодробнее

Nivolumab + Ipilimumab vs Platinum-doublet Chemotherapy as First-line Treatment for Advanced NSCLCПодробнее

Ipilimumab plus nivolumab with sacituzumab govitecan in mUCПодробнее

Nivolumab Plus Ipilimumab vs Chemotherapy in Unresectable MesotheliomaПодробнее

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRCПодробнее

Ipilimumab/Nivolumab in First-Line mRCCПодробнее

Nivolumab plus gemcitabine-cisplatin shows benefit for locally advanced mUCПодробнее

Cancer Immunotherapy with Nivolumab Plus Ipilimumab Vs. Chemotherapy: Insights from CheckMate 227Подробнее

Dr. Chiang on Toxicities with Ipilimumab Plus Nivolumab in Small Cell Lung CancerПодробнее

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLCПодробнее

FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory advance...Подробнее

HCRN-GU16-260: nivolumab and salvage nivolumab-ipilimumab in patients with advanced RCCПодробнее

CheckMate 9LA: First-line nivolumab + ipilimumab + 2 cycles chemotherapy vs 4 cycles chemo in aN...Подробнее

Nivolumab Plus Ipilimumab in Advanced MelanomaПодробнее

Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCCПодробнее

Phase II Data Suggest Benefit With Nivolumab/Ipilimumab Combination in mCRCПодробнее

CheckMate 648: Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as (1L) treatment for a...Подробнее